AdvanCell to Present Updated Phase 1b Results from the TheraPb Trial at ESMO Congress 2026
Updated data support recommended Phase 2 dosage of 212Pb-ADVC001, AdvanCell's Lead-212 based PSMA-targeted therapy for…
AdvanCell Admin21 July 2026
AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructure
Oversubscribed financing led by Ally Bridge Group and co-led by Alpha Wave, with participation from…
AdvanCell Establishes U.S. Global Headquarters and Secures Flagship Manufacturing Facility in Greater Boston to Drive Growth Strategy
New 128,000-square-foot facility in Andover will serve as U.S. global headquarters and future manufacturing center…
DesignQ Developer22 June 2026
AdvanCell Strengthens Executive Leadership to Accelerate U.S. Expansion and Scale its Global Targeted Alpha Therapy Platform
Justyna Kelly, MSc, joins as Chief Technology Officer and François Gaudet, PhD, joins as Chief…
AdvanCell Admin8 June 2026
Dr. Oliver Sartor interviews AdvanCell CMO Dr. Anna Karmann on TheraPb Phase 2 for UroToday
Anna Karmann outlines AdvanCell's Lead-212 alpha-emitting radioligand therapy program, covering the phase one experience and…
AdvanCell Admin1 April 2026
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 2026
-- The trial uses a response-driven dosing strategy and extended treatment across three prostate cancer…
AdvanCell Admin24 February 2026
AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need
Brisbane, Australia and Boston, USA – February 2, 2026 – AdvanCell, a clinical-stage radiopharmaceutical company…
DesignQ Developer2 February 2026
AdvanCell Announces Upcoming Presentation of TheraPb Phase 2 Expansion Study Design at ASCO Genitourinary Cancers Symposium 2026
Sydney, Australia and Boston, USA – January 22, 2026 – AdvanCell, a clinical-stage radiopharmaceutical company…
AdvanCell Admin22 January 2026
AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies
Thorium-228 (228Th) is the parent isotope and key starting material to produce the alpha-emitter Lead-212…
DesignQ Developer8 December 2025
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer
Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at…
DesignQ Developer2 December 2025
